Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin

A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-007-0542-4 ◽

2007 ◽

Vol 61 (5) ◽

pp. 847-853 ◽

Cited By ~ 5

Author(s):

Ruey-Long Hong ◽

Ching-Hung Lin ◽

Tsu-Yi Chao ◽

Woei-You Kao ◽

Cheng-Hsu Wang ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Salvage Chemotherapy ◽

Previously Treated

Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.818 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 818-818

Author(s):

J.-P. Guastalla ◽

A.-C. Hardy-Bessard ◽

J.-F. Geay ◽

H. Cure ◽

I. Ray-Coquard ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.818 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 818-818

Author(s):

J.-P. Guastalla ◽

A.-C. Hardy-Bessard ◽

J.-F. Geay ◽

H. Cure ◽

I. Ray-Coquard ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000217552.69036.16 ◽

2006 ◽

Vol 29 (3) ◽

pp. 267-275 ◽

Cited By ~ 9

Author(s):

Hugues Bourgeois ◽

Aur??lie Ferru ◽

Alain Lortholary ◽

Thierry Delozier ◽

Mich??le Boisdron-Celle ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2017.10.005 ◽

2018 ◽

Vol 18 (1) ◽

pp. e143-e149 ◽

Cited By ~ 9

Author(s):

Amy E. Chang ◽

Qian V. Wu ◽

Isaac C. Jenkins ◽

Jennifer M. Specht ◽

Vijayakrishna K. Gadi ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin

Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer

The Breast ◽

10.1016/j.breast.2008.03.009 ◽

2008 ◽

Vol 17 (5) ◽

pp. 517-522 ◽

Cited By ~ 2

Author(s):

Zee-Wan Wong ◽

Peter Cher-Siang Ang ◽

Balram Chowbay ◽

Nan-Soon Wong ◽

Hui-Ti See ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Asian Women ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Multicenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study

Annals of Oncology ◽

10.1093/annonc/mdz242.042 ◽

2019 ◽

Vol 30 ◽

pp. v124-v125

Author(s):

E. López-Miranda ◽

S. Di Cosimo ◽

E. Brain ◽

M. Ravnik ◽

S. Escrivá-de-Romaní ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase I Trial ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Multicenter Phase

Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)

10.1158/1538-7445.sabcs16-ot1-02-03 ◽

2017 ◽

Author(s):

E López-Miranda ◽

E Brain ◽

C Saura ◽

J Gligorov ◽

C Dubot ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Phase I ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Multicenter Clinical Trial ◽

Her2 Positive

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-021-04245-x ◽

2021 ◽

Author(s):

Filipa Lynce ◽

James T. Williams ◽

Meredith M. Regan ◽

Craig A. Bunnell ◽

Rachel A. Freedman ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase I Study ◽

Metastatic Breast ◽

Weekly Paclitaxel

Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study

Annals of Oncology ◽

10.1093/annonc/mds052 ◽

2012 ◽

Vol 23 (10) ◽

pp. 2599-2605 ◽

Cited By ~ 5

Author(s):

R.P. Collea ◽

F.W. Kruter ◽

J.E. Cantrell ◽

T.K. George ◽

S. Kruger ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin